Trends in obesity and overweight-related office visits and drug prescriptions in Canada, 1998 to 2004.
OBJECTIVE
Obesity and overweight are affecting increasing numbers of Canadians and have received considerable amounts of medical, governmental, and media attention in recent years. This study sought to determine whether this rise in prevalence and awareness has resulted in an increased frequency of obesity and overweight-related office visits or antiobesity drug prescriptions over the past 5 years.


METHODS
Data from IMS Health Canada were used to derive nationally representative estimates of trends in the annual number of obesity and overweight-related office visits (1999 to 2003) and the quarterly prescription volume of antiobesity drugs (July 1998 to March 2003) in Canada.


RESULTS
The number of obesity and overweight-related office visits increased by 20% between 1999 and 2000 but then remained constant. The number of antiobesity drug prescriptions peaked in 2001 and has since declined, with parallel trends being observed for all individual agents. In contrast, the overall frequency of office visits and drug prescriptions in Canada (for any reason) progressively increased over the study period. Middle-aged women were the most common type of patient to seek physician advice regarding obesity, and general practitioners were the most common type of physician visited.


CONCLUSIONS
Increases in the prevalence and awareness of obesity have not resulted in major increases in office visits or drug prescriptions for this condition over the past 5 years. A number of patient, physician, and drug-related factors may explain these results, which are likely a reflection primarily of the current lack of effective weight loss strategies for obese individuals.
Padwal
Raj S
RS
Division of General Internal Medicine, 2E3.22 Walter C. Mackenzie Health Sciences Center, University of Alberta Hospital, 8440-112th Street, Edmonton, AB, Canada, T6G 2B7. rpadwal@ualberta.ca.
D000328:Adult; D000368:Aged; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D002170:Canada / Q000453:epidemiology; D003503:Cyclobutanes / Q000627:therapeutic use; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D007783:Lactones / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy / Q000453:epidemiology*; D009819:Office Visits / Q000706:statistics & numerical data / Q000639:trends*; D000077403:Orlistat; D050177:Overweight; D015995:Prevalence
D019440:Anti-Obesity Agents; D003503:Cyclobutanes; D007783:Lactones; D000077403:Orlistat; C058254:sibutramine